title: Should we embrace or ablate our urge to (ovarian) suppress?
authors.affiliation: University of Pittsburgh Cancer Institute; University of Pittsburgh Medical Center CancerCenter; and University of Pittsburgh Medical Center Magee-Womens Breast Cancer Program, Pittsburgh, PA.
authors.forename: Rachel C
authors.initials: RC
authors.lastname: Jankowitz
authors.affiliation: University of Pittsburgh Cancer Institute; University of Pittsburgh Medical Center CancerCenter; and University of Pittsburgh Medical Center Magee-Womens Breast Cancer Program, Pittsburgh, PA.
authors.forename: Shannon
authors.initials: S
authors.lastname: Puhalla
authors.affiliation: University of Pittsburgh Cancer Institute; University of Pittsburgh Medical Center CancerCenter; and University of Pittsburgh Medical Center Magee-Womens Breast Cancer Program, Pittsburgh, PA davidsonne@upmc.edu.
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Davidson
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D010053:Ovary / Q000187:drug effects*; D013629:Tamoxifen / Q000008:administration & dosage*
chemical_list: D013629:Tamoxifen